Clinical Research Directory
Browse clinical research sites, groups, and studies.
Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease
Sponsor: Kamau Therapeutics
Summary
This study is a first-in-human, single-arm, open-label Phase I/II study of nula-cel in approximately 15 participants, diagnosed with severe Sickle Cell Disease. The primary objective is to evaluate safety of the treatment in this patient population, as well as preliminary efficacy and pharmacodynamic data.
Official title: A Phase I/II Study of Nula-cel in Autologous CD34+ Hematopoietic Stem Cells to Convert HbS to HbA for Treating Severe Sickle Cell Disease
Key Details
Gender
All
Age Range
12 Years - 40 Years
Study Type
INTERVENTIONAL
Enrollment
15
Start Date
2021-11-15
Completion Date
2028-12-31
Last Updated
2026-03-11
Healthy Volunteers
No
Conditions
Interventions
nula-cel Drug Product
nula-cel is administered via IV infusion following a myeloablative conditioning regimen
Locations (4)
Children's Hospital Los Angeles
Los Angeles, California, United States
Lucile Packard Children's Hospital
Palo Alto, California, United States
Washington University
St Louis, Missouri, United States
Nationwide Children's Hospital
Columbus, Ohio, United States